BRPI0915781A2 - oxazolopiridimas como agonista do receptor edg-1 - Google Patents
oxazolopiridimas como agonista do receptor edg-1Info
- Publication number
- BRPI0915781A2 BRPI0915781A2 BRPI0915781A BRPI0915781A BRPI0915781A2 BR PI0915781 A2 BRPI0915781 A2 BR PI0915781A2 BR PI0915781 A BRPI0915781 A BR PI0915781A BR PI0915781 A BRPI0915781 A BR PI0915781A BR PI0915781 A2 BRPI0915781 A2 BR PI0915781A2
- Authority
- BR
- Brazil
- Prior art keywords
- oxazolopyridimes
- edg
- receptor agonist
- agonist
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08290694 | 2008-07-15 | ||
PCT/EP2009/004770 WO2010006704A1 (en) | 2008-07-15 | 2009-07-02 | Oxazolopyrimidines as edg-1 receptor agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0915781A2 true BRPI0915781A2 (pt) | 2015-11-10 |
Family
ID=39967817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0915781A BRPI0915781A2 (pt) | 2008-07-15 | 2009-07-02 | oxazolopiridimas como agonista do receptor edg-1 |
Country Status (20)
Country | Link |
---|---|
US (1) | US8735387B2 (pt) |
EP (2) | EP2583720A1 (pt) |
JP (1) | JP5449346B2 (pt) |
KR (1) | KR20110042286A (pt) |
CN (1) | CN102159582B (pt) |
AR (1) | AR072496A1 (pt) |
AU (1) | AU2009270511B2 (pt) |
BR (1) | BRPI0915781A2 (pt) |
CA (1) | CA2730843A1 (pt) |
CL (1) | CL2011000071A1 (pt) |
CO (1) | CO6331436A2 (pt) |
IL (1) | IL210639A0 (pt) |
MA (1) | MA32455B1 (pt) |
MX (1) | MX2011000211A (pt) |
NZ (1) | NZ590377A (pt) |
RU (1) | RU2503680C2 (pt) |
TW (1) | TW201016707A (pt) |
UY (1) | UY31981A (pt) |
WO (1) | WO2010006704A1 (pt) |
ZA (1) | ZA201008786B (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR079980A1 (es) | 2010-01-13 | 2012-03-07 | Sanofi Aventis | Derivados de oxazolopirimidina sustituida en 2,5,7 |
AR079981A1 (es) | 2010-01-13 | 2012-03-07 | Sanofi Aventis | Derivados de acido carboxilico que comprenden un anillo de oxoazolopirimidina 2,5,7- sustituido |
CN102834400B (zh) * | 2010-01-14 | 2015-06-10 | 赛诺菲 | 2,5-取代的*唑并嘧啶衍生物 |
PL2523962T3 (pl) * | 2010-01-14 | 2014-05-30 | Sanofi Sa | Pochodne kwasu karboksylowego posiadające pierścień 2,5-podstawionej oksazolopirymidyny |
DK2523960T3 (da) * | 2010-01-14 | 2014-01-20 | Sanofi Sa | Heterocykliske carboxylsyrederivater med en 2,5-substitueret oxazolopyrimidinring |
EP2719687B1 (en) | 2010-03-12 | 2015-09-16 | Nippon Soda Co., Ltd. | Process to make a bromopicoline derivative |
US8735402B2 (en) | 2011-07-07 | 2014-05-27 | Sanofi | Cycloalkyloxycarboxylic acid derivatives |
US9321787B2 (en) * | 2011-07-07 | 2016-04-26 | Sanofi | Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring |
US8907093B2 (en) | 2011-07-07 | 2014-12-09 | Sanofi | Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring |
US8580816B2 (en) * | 2011-07-07 | 2013-11-12 | Sanofi | Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring |
CN104540835B (zh) | 2012-04-26 | 2017-08-08 | 百时美施贵宝公司 | 用于治疗血小板聚集的作为蛋白酶激活受体4(par4)抑制剂的咪唑并噻二唑衍生物 |
SG11201406757SA (en) * | 2012-04-26 | 2014-11-27 | Bristol Myers Squibb Co | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
EP3297990A4 (en) * | 2015-03-26 | 2019-01-23 | The Florey Institute Of Neuroscience And Mental Health | MODULATORS OF SODIUM CHANNELS |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3679682A (en) * | 1970-04-23 | 1972-07-25 | Fmc Corp | CERTAIN 5H-ISOXAZOLO{8 5,4-d{9 PYRIMIDIN-4-ONES |
CA2449188A1 (en) * | 2001-05-14 | 2002-11-21 | Novartis Ag | Oxazolo-and furopyrimidines and their use in medicaments against tumors |
EP1469863A2 (en) | 2002-01-18 | 2004-10-27 | Merck & Co., Inc. | Selective s1p1/edg1 receptor agonists |
JP2006524672A (ja) | 2003-04-25 | 2006-11-02 | ユニバーシティー・カッレッジ・カーディフ・コンサルタンツ・リミテッド | ウイルス感染の治療において使用するための複素環式化合物 |
CA2523677A1 (en) * | 2003-04-30 | 2004-11-11 | Novartis Ag | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators |
CA2524048C (en) * | 2003-05-19 | 2013-06-25 | Irm Llc | Immunosuppressant compounds and compositions |
US20070027156A1 (en) | 2003-09-09 | 2007-02-01 | Hisao Nakai | Crf antagonists and heterobicyclic compounds |
JP4773972B2 (ja) | 2003-12-17 | 2011-09-14 | メルク・シャープ・エンド・ドーム・コーポレイション | S1P(Edg)受容体作働薬としての(3,4−ジ置換)プロパンカルボン酸 |
WO2005069865A2 (en) | 2004-01-13 | 2005-08-04 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
WO2005123677A1 (en) | 2004-06-16 | 2005-12-29 | Actelion Pharmaceuticals Ltd | 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents |
WO2006010379A1 (en) | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as immunosuppressive agents |
WO2006047195A2 (en) | 2004-10-22 | 2006-05-04 | Merck & Co., Inc. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists |
AU2006317689B2 (en) * | 2005-11-23 | 2013-07-25 | Epix Delaware, Inc. | S1P receptor modulating compounds and use thereof |
EP1900729A1 (en) * | 2006-09-15 | 2008-03-19 | Novartis AG | Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors |
-
2009
- 2009-07-02 EP EP13151034.9A patent/EP2583720A1/en not_active Withdrawn
- 2009-07-02 CA CA2730843A patent/CA2730843A1/en not_active Abandoned
- 2009-07-02 MX MX2011000211A patent/MX2011000211A/es active IP Right Grant
- 2009-07-02 KR KR1020117001113A patent/KR20110042286A/ko not_active Application Discontinuation
- 2009-07-02 US US13/003,125 patent/US8735387B2/en not_active Expired - Fee Related
- 2009-07-02 EP EP09776914A patent/EP2318415B1/en active Active
- 2009-07-02 AU AU2009270511A patent/AU2009270511B2/en not_active Ceased
- 2009-07-02 NZ NZ590377A patent/NZ590377A/en not_active IP Right Cessation
- 2009-07-02 RU RU2011105388/04A patent/RU2503680C2/ru not_active IP Right Cessation
- 2009-07-02 BR BRPI0915781A patent/BRPI0915781A2/pt not_active IP Right Cessation
- 2009-07-02 JP JP2011517773A patent/JP5449346B2/ja not_active Expired - Fee Related
- 2009-07-02 WO PCT/EP2009/004770 patent/WO2010006704A1/en active Application Filing
- 2009-07-02 CN CN200980135883.4A patent/CN102159582B/zh not_active Expired - Fee Related
- 2009-07-13 AR ARP090102624A patent/AR072496A1/es not_active Application Discontinuation
- 2009-07-13 UY UY0001031981A patent/UY31981A/es not_active Application Discontinuation
- 2009-07-13 TW TW098123561A patent/TW201016707A/zh unknown
-
2010
- 2010-12-07 ZA ZA2010/08786A patent/ZA201008786B/en unknown
-
2011
- 2011-01-05 MA MA33493A patent/MA32455B1/fr unknown
- 2011-01-12 CL CL2011000071A patent/CL2011000071A1/es unknown
- 2011-01-13 IL IL210639A patent/IL210639A0/en unknown
- 2011-01-14 CO CO11003596A patent/CO6331436A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US8735387B2 (en) | 2014-05-27 |
AR072496A1 (es) | 2010-09-01 |
EP2318415A1 (en) | 2011-05-11 |
CL2011000071A1 (es) | 2011-05-06 |
MA32455B1 (fr) | 2011-07-03 |
TW201016707A (en) | 2010-05-01 |
KR20110042286A (ko) | 2011-04-26 |
UY31981A (es) | 2010-02-26 |
IL210639A0 (en) | 2011-03-31 |
JP5449346B2 (ja) | 2014-03-19 |
EP2318415B1 (en) | 2013-02-20 |
CA2730843A1 (en) | 2010-01-21 |
MX2011000211A (es) | 2011-03-03 |
WO2010006704A1 (en) | 2010-01-21 |
US20110190490A1 (en) | 2011-08-04 |
CN102159582A (zh) | 2011-08-17 |
EP2583720A1 (en) | 2013-04-24 |
JP2011527994A (ja) | 2011-11-10 |
AU2009270511B2 (en) | 2013-07-18 |
CN102159582B (zh) | 2014-05-07 |
AU2009270511A1 (en) | 2010-01-21 |
NZ590377A (en) | 2011-11-25 |
RU2011105388A (ru) | 2012-08-20 |
CO6331436A2 (es) | 2011-10-20 |
RU2503680C2 (ru) | 2014-01-10 |
ZA201008786B (en) | 2012-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LTPA2020513I1 (lt) | S1P receptoriaus agonisto dozavimas | |
BRPI0915781A2 (pt) | oxazolopiridimas como agonista do receptor edg-1 | |
DK2448963T3 (da) | T-celle receptorer | |
FI20080524A0 (fi) | Insertteri | |
ATE535521T1 (de) | Hydroxymethyl-pyrrolidine als beta-3-adrenerge rezeptoragonisten | |
BRPI0919228A2 (pt) | um inseridor | |
BRPI0919071A2 (pt) | um inseridor | |
CR10926A (es) | Nuevas 2-aminooxazolinas como ligandos taar1 | |
BRPI0922845A2 (pt) | pirazol-4-n-alcoxicarboxamidas como microbiocidas | |
DK2340021T3 (da) | Substituerede pyrrolidin-2-carboxamider | |
BRPI0916551A2 (pt) | dispositivo eletroquímico | |
BRPI0820813A2 (pt) | Agendamento para gerenciamento de dispositivo móvel | |
BRPI0918064A2 (pt) | distribuidor de substância | |
BRPI0909160A2 (pt) | rolamentos | |
BR112012002824A2 (pt) | agonistas de receptor de esfingosina-1-fosfato | |
NO2019028I1 (no) | Cabergoline | |
BRPI0915562A2 (pt) | tamis melhorado | |
DE112009000730A5 (de) | Gleitlager | |
BRPI0915442A2 (pt) | tamis melhorado | |
NO20081295L (no) | Dempeanordning | |
BRPI0918656A2 (pt) | dosador | |
BRPI0910741A2 (pt) | arilciclopentenos substituídos como agonistas de prostaglantina ep2 | |
BRPI0907519A2 (pt) | Antagonistas farmacoforos-pde4-muscarínicos duais | |
MA31558B1 (fr) | Arriere-plan technologique | |
TH106988B (th) | ออกซะโซโลพิริมิดีนเป็น Edg-1 รีเซพเตอร์ แอกโกนิสท์ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2376 DE 19-07-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |